# FDA recall D-886-2013

> **Sanofi-Synthelabo** · Class II · drug recall initiated 2013-02-26.

## Product

Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887

## Reason for recall

Subpotent Drug:  During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.

## Distribution

Canada

## Key facts

- **Recall number:** D-886-2013
- **Recalling firm:** Sanofi-Synthelabo
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2013-02-26
- **Report date:** 2013-08-21
- **Termination date:** 2014-06-06

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Laval, Canada

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-886-2013

## Citation

> AI Analytics. FDA recall D-886-2013. Retrieved 2026-09-21 from https://api.ai-analytics.org/recall/D-886-2013. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*